Rafferty Asset Management LLC Sells 65,538 Shares of bluebird bio, Inc. (NASDAQ:BLUE)

Rafferty Asset Management LLC lowered its stake in shares of bluebird bio, Inc. (NASDAQ:BLUEFree Report) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,425,873 shares of the biotechnology company’s stock after selling 65,538 shares during the period. Rafferty Asset Management LLC owned 1.30% of bluebird bio worth $1,968,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Citigroup Inc. lifted its position in shares of bluebird bio by 5.8% in the third quarter. Citigroup Inc. now owns 557,969 shares of the biotechnology company’s stock worth $1,696,000 after buying an additional 30,532 shares in the last quarter. Deutsche Bank AG boosted its position in shares of bluebird bio by 80.8% during the 3rd quarter. Deutsche Bank AG now owns 692,881 shares of the biotechnology company’s stock valued at $2,106,000 after acquiring an additional 309,690 shares during the last quarter. Bleichroeder LP purchased a new position in shares of bluebird bio in the third quarter valued at $2,736,000. Aigen Investment Management LP bought a new stake in bluebird bio in the third quarter worth $34,000. Finally, Vanguard Group Inc. increased its position in bluebird bio by 0.8% in the third quarter. Vanguard Group Inc. now owns 5,617,460 shares of the biotechnology company’s stock worth $17,077,000 after purchasing an additional 46,216 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Stock Down 1.0 %

Shares of NASDAQ BLUE opened at $0.91 on Monday. bluebird bio, Inc. has a twelve month low of $0.85 and a twelve month high of $5.53. The business has a fifty day simple moving average of $1.02 and a two-hundred day simple moving average of $1.51. The firm has a market cap of $98.95 million, a PE ratio of -1.22 and a beta of 0.81.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BLUE. Wedbush reduced their target price on shares of bluebird bio from $1.72 to $1.68 and set a “neutral” rating on the stock in a report on Tuesday, March 19th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $6.00 target price on shares of bluebird bio in a report on Wednesday, March 27th. HSBC dropped their price objective on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating for the company in a research note on Tuesday, March 5th. StockNews.com upgraded shares of bluebird bio to a “sell” rating in a report on Thursday, March 28th. Finally, Wells Fargo & Company decreased their price objective on shares of bluebird bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a research note on Wednesday, March 27th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, bluebird bio currently has a consensus rating of “Hold” and an average price target of $5.46.

View Our Latest Report on bluebird bio

bluebird bio Company Profile

(Free Report)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

Featured Articles

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.